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Abstract
As advances in the treatment of HIV are now allowing patients a longer life 
span, further comorbidities become apparent. This includes sensory neuropathy 
(HIV-SN) which can affect a patient’s quality of life. Here, we review factors 
influencing HIV-SN in patients receiving antiretroviral therapy that promotes this 
condition and in the modern era when these therapies have been withdrawn. This 
has halved the incidence of HIV-SN, but the condition remains significant in the 
lives of many sufferers. Genetic polymorphisms that influence pathogenesis of 
HIV-SN have indicated likely mechanisms, but studies of skin biopsies and animal 
models are needed to confirm the roles of the encoded proteins.
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1. Introduction
Management of HIV patients is now focused on their quality of life as anti-
retroviral therapy (ART) increases life expectancy. However, with longer lives, a 
growing number of patients experience a neurological disorder that predominantly 
affects small fibers. HIV-associated sensory neuropathy (HIV-SN) may arise not 
only as a result of HIV infection itself but also as a side effect of ART. The clinical 
pictures triggered by HIV infection or ART are very similar and include neuropathic 
pain, tingling sensation, and numbness [1–3]. HIV-SN is one of the most common 
complications of HIV infection.
The incidence and prevalence of HIV-SN vary widely—perhaps because most 
studies do not distinguish between neuropathy due to HIV itself and due to ART 
regimens with different risk profiles. Cross-sectional studies including patients 
receiving ART identify HIV-SN in 16–50% of HIV patients [4–6]. ART that includes 
the non-nucleotide reverse transcriptase inhibitor (NNRTI), stavudine (d4T), is 
associated with high prevalence of HIV-SN. The prevalence in Melbourne was up 
to 42%, whereas in Kuala Lumpur and Jakarta, the reported level was lower, 19 and 
34%, respectively [7]. Stavudine is no longer in first-line therapy, and the preva-
lence of HIV-SN is almost halved (14.2%) compared to data from the same clinic in 
Indonesia when patients received stavudine [8].
In untreated patients, the risk factors for HIV-SN were severe HIV disease marked 
by low numbers of CD4+ T cells and high viral loads (HIV RNA) in plasma. In the era 
of ART (including stavudine), the risk factors of HIV-SN included older age, height, 
<50 CD4+ T cells/mm3, malnutrition, and concurrent diabetes [1, 7, 9, 10]. HIV-SN 
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was also more common in African-Americans [3] and Hispanics [11]. Genetic 
polymorphisms may alter risk for HIV-SN in Africans [12–14], Asians [15], and 
Caucasians [16]. These factors are discussed in more detail here.
2. Clinical features and diagnostic criteria
There are two forms of HIV-SN—distal symmetrical polyneuropathy in HIV 
(DSP) and antiretroviral toxic neuropathy (ATN). DSP arises at later stages of HIV 
infection, while ATN is caused by neurotoxic effects of antiretroviral drugs [10, 17]. 
These two forms cannot be distinguished clinically, so they are grouped as HIV-SN 
when seen in patients receiving ART.
The most frequent symptoms of HIV-SN are pain, numbness, and burning 
sensations. The symptoms can be progressive, predominantly affecting the soles 
of the feet and may become more severe at night. Physical examination may reveal 
hyperalgesia and allodynia, with absent physiological reflexes and sensory loss 
in the distal limb segments, including sensitivity to vibration [1, 9–11]. Clinical 
symptoms usually occur first on the lower limbs for several months but may spread 
upward. Since HIV-SN predominantly affects small nerve fibers, the clinical signs 
can also manifest as autonomic neuropathy with postural hypotension and urinary 
dysfunction [18]. Guidelines for the diagnosis and management of HIV-SN are 
available [e.g., https://www.hiv.va.gov/provider/manual-primary-care/peripheral-
neuropathy.asp] but require adaptation to accommodate differences between 
patient populations, structures of medical care, and available resources.
Perhaps, the optimal tool to screen HIV-SN is AIDS Clinical Trial Group Brief 
Peripheral Neuropathy Screening Test (ACTG BPNST). This test has been used in 
many countries including Australia, the USA, India, South Africa, and Indonesia. 
It is relatively inexpensive, is fairly easy to do, and takes less than 10 minutes to 
perform but has low sensitivity. A study comparing BPNST to modified Total 
Neuropathy Scores (mTNS) in HIV patients on ART (including d4T, ddI, ddC) 
found that the sensitivity of BPNST was 49%, whereas the specificity was high at 
88% [17]. Peripheral neuropathy can be diagnosed if there is ≥1 symptom assessed 
in the BPNST list and one of the following signs: decreased Achilles reflexes or 
decreased sensibility to vibration when a tuning fork is held on a toe. This definition 
means that patients with two abnormal signs but no symptoms are not considered 
to have HIV-SN. This may contribute to variations in the prevalence of peripheral 
neuropathy in HIV reported in various studies. Some studies consider this inter-
mediate group as asymptomatic peripheral neuropathy with the assumption that 
they can become symptomatic in time. Ellis et al. defined peripheral neuropathy as 
a decrease in Achilles tendon reflexes or decreased perception of vibration in both 
legs. The sensitivity increased by 80% but the specificity decreased to 59% [19].
Clinically, peripheral neuropathy can also be classified as small- or large-fiber 
neuropathy. The latter manifests as the loss of joint position and vibration sense 
and sensory ataxia, whereas small-fiber neuropathy manifests as neuropathic pain, 
impairment of temperature sensing, and autonomic function. A nerve conduc-
tion study (NCS) can include sensory and motor nerve conduction and help in 
documenting sensory motor deficits that mainly affect large-fiber nerves [20]. As 
HIV-SN is a predominately small-fiber neuropathy, NCS is often normal [21]. In 
HIV-SN patients, ATN- and HIV-associated DSP often cannot be distinguished 
since patients can have both types at same time. However, there are some evidences 
that ATN primarily impairs small-fiber nerves, whereas HIV-associated neuropathy 
(DSP) has been linked to large-fiber nerves [22, 23].
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Stimulated skin wrinkling (SSW) test is a method to assess small nerve fiber 
function using exposure to eutectic mixture of local anesthetic. It has been shown 
to correlate with intraepidermal nerve fiber density (IENFD) in patients with 
a sensory neuropathy [24] and has high sensitivity compared to other assess-
ments of small-fiber neuropathy in diabetic patients [25]. Skin wrinkling occurs 
as a result of vasoconstriction in the glabrous skin, mediated by postganglionic 
sympathetic fibers [26]. Other assessments that have been used to detect small-
fiber neuropathy in HIV-SN patients include quantitative sudomotor axon reflex 
tests (QSART) [27], quantitative sensory tests (QST) [18], and sympathetic skin 
responses (SSR) [22, 23].
Skin biopsies are the gold standard for the detection of damage to small-diameter 
sensory nerves, including non-myelinated and myelinated intraepidermal nerve 
fibers. Lower nerve fiber densities have been demonstrated in patients with HIV-SN 
[18]. Studies have used several different techniques. The European Federation of 
Neurological Societies recommended a biopsy of the skin to a depth of 3 mm by 
using a skin punch biopsy on the distal limbs to calculate the linear density or nerve 
fibers with a minimum of 50 μm-thick slices, fixed in a 2% solution of parafor-
maldehyde-lysine-periodate (2% PLP). Immunohistochemical staining techniques 
recommended are bright-field immunohistochemistry and indirect immunofluo-
rescence [28]. PGP9.5 immunofluorescence allows nerves to be visualized using a 
confocal microscope [29]. Smaller intraepidermal nerve fiber densities (IENFD) 
in HIV-SN patients correlated with the clinical and electrophysiological severity 
[30]. Skin biopsies can also be used to identify cells and mediators that contribute to 
SN. These are discussed later in this chapter.
3. Clinical factors influence the risk of HIV-SN
Analyses of the risk factor of HIV-SN require that we consider the condition in 
three distinct eras—(1) pre-ART, (2) the use of combination ART that included 
stavudine (d4T), and (3) the use of non-neurotoxic ART. In the pre-ART era, the 
risk factors for developing HIV-SN included HIV disease severity, low CD4+ T-cell 
counts, high viral load, and older age [31, 32]. In the second era, the risk factors 
are older age, height, low nadir CD4+ T-cell counts, HIV duration, malnutrition, 
diabetes mellitus, dyslipidemia, and the use of neurotoxic drugs (usually stavudine; 
see Table 1; [7, 14, 15, 33, 34]). Stavudine is no longer recommended by the WHO 
as first-line ART and is now rarely used anywhere in the world, but HIV-SN has 
Demographic risk factors Genetic risk factors
Low nadir CD4+ T-cell count
HIV duration
Age
Height
High plasma HIV RNA
Diabetes mellitus
Malnutrition
Neurotoxic drugs
• NRTI: stavudine, didanosine
• Protease inhibitors: indinavir, ritonavir, saquinavir
Race (more common in African populations)
Polymorphisms in
• Mitochondrial DNA (mtDNA)
• HFE (affecting iron metabolism)
• Cytokine genes (IL4, IL10, IL12B)
• TNF gene block (central MHC)
• P2X4R, P2X7R (purinergic receptors)
• CAMKK2 (affecting neuronal repair)
Table 1. 
Genetic and demographic risk factors affecting HIV-SN in patients receiving ART.
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not disappeared. The risk factors of HIV-SN in patients on ART without stavudine 
are almost the same as in the pre-ART era—high plasma viral load and older age 
[8]. Isoniazid is widely used as therapy for tuberculosis and has been recognized 
as a risk factor for neuropathy for a long time. It remains weakly associated with 
HIV-SN even though patients receiving isoniazid are also given B6 supplementa-
tion to prevent neuropathy. Protease inhibitor (PI) exposure may be a risk factor 
of HIV-SN. Lopinavir, indinavir, and ritonavir, but not nelfinavir, were associated 
with neuropathy in one study [35].
4. Genetic risk factors
The risk of HIV-SN cannot be correlated with a single genetic variant, so candi-
date genes are discussed separately (see Table 1). It is of interest to determine if any 
aligns with the greater sensitivity of individuals of African descent [13, 14, 36].
4.1 Genes in linkage disequilibrium with TNF or encoding components of 
pathways regulated by TNF
In patients receiving stavudine, haplotypic combinations of alleles of single-
nucleotide polymorphisms (SNP) spanning the tumor necrosis factor (TNF) block 
in the central major histocompatibility complex (MHC) associate with variations 
in the prevalence of HIV-SN, but the associations were different in Africans and 
Asians [12]. For example, a polymorphism in intron 10 of BAT1 (marking an MHC 
haplotype associated with several inflammatory disorders) and a polymorphism 
in the promoter region of the TNFA gene (TNF-1031) were associated with an 
increased risk of HIV-SN in Caucasians [37]. TNF-1031*2 is associated with 
an increased risk of HIV-SN in Indonesian HIV-positive patients who receive 
stavudine [15, 16]. However, in Africans, different SNP alleles were found in 
linkage disequilibrium with TNF-1031*2, so TNF-1031*2 was not associated with 
HIV-SN. These findings link HIV-SN with an unknown SNP in the TNF block 
marked by (but distinct from) TNF-1031. The link between HIV-SN and inflam-
mation was supported by studies linking IL4 genotypes with HIV-SN in Africans 
receiving stavudine [13].
4.2 The P2X7R, P2X4R, and CAMKK2 gene cluster: Inflammation and  
neuronal repair
Goullee et al. linked SNP in three genes P2X7R, P2X4R, and CAMKK2 with 
HIV-SN in African patients treated with stavudine. In a logistic regression 
model which included demographic analyses, SNP in CAMKK2, and to a lesser 
extent P2X7R and P2X4R, demonstrated independent associations with HIV-SN 
(p < 0.0001; R2 = 0.19) [14].
The P2X7R receptor is expressed by microglia and may be involved in neuro-
pathic pain, as its ablation or inhibition in animal models of neuropathy can reduce 
responses to painful stimuli [38]. Conversely, stimulation of P2X7R will increase 
the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα [39] as 
well as pro-inflammatory chemokines such as CXCL2 and CCL3, which have been 
implicated in neuropathic pain [40, 41].
In animal studies, P2X4R was activated in spinal microglial cells in rats with 
induced pain [42]. Mice with disrupted P2X4R genes showed reduced pain response 
in two models of chronic pain (inflammatory and neuropathic) [43]. P2X4R is 
upregulated after peripheral nerve injury which results in increased activity of 
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mitogen p38 [44]. This process initiates the release of brain-derived neurotropic 
factor (BDNF). BDNF induces neuronal hyperexcitability through interaction with 
the TrkB receptor [45, 46].
The CAMKK2 gene encodes calcium-/calmodulin-dependent protein kinase 2 
(CaMKK2), which acts as a pervasive second messenger of Ca2+ in many cellular 
functions such as energy balance, neuronal differentiation, and inflammation 
[47]. CaMKK2 plays a role in neural plasticity and neurite growth by activating 
another protein kinase CaMKI [48]. CAMKK2 and P2X4R polymorphisms affect 
TNFα production in vitro. This suggests a mechanism for their impact on HIV-SN 
[49]. Hence, polymorphisms in CAMKK2 may affect inflammation or neuronal 
growth.
4.3 Mitochondrial haplotypes and iron metabolism
The process of mitochondrial toxicity induced by ART is not a simple drug 
toxicity, but mitochondrial DNA (mtDNA) SNP has a role in developing HIV-SN 
in patients receiving NRTI. SNP in African mtDNA haplogroup L1c and European 
haplogroup J is associated with decreased prevalence of HIV-SN compared with all 
other haplogroups [36]. Moreover, Thai persons belonging to mtDNA haplogroup B 
were more likely to develop HIV-SN [50].
HIV-1 Nef protein may influence iron levels via interactions with the hemo-
chromatosis protein HFE in humans [51]. In an observational prospective study, 
Kallianpur et al. suggested that disruption of iron homeostasis due to HIV infection 
might damage neurons and potentially lead to HIV-SN. They presented evidence 
that the HFE C282Y mutation may be a protective factor in HIV patients using NRTI 
[52]. They subsequently linked polymorphisms in iron management genes with 
increased risk (TF, CP, ACO1, BMP6, B2M) and reduced risk (TF, TFRC, BMP6, 
ACO1, SLC11A2, FXN) of HIV-SN [53].
5. The pathophysiology of HIV-SN
The pathophysiology of HIV-SN is not completely understood, but there are 
several promising theories. It remains unclear whether HIV inflicts direct damage in 
the nerve body of dorsal root ganglia (DRG) or damages nerve fibers; both will lead 
to the development of distal axonopathies. HIV causes distal axon degeneration, 
reduction of nerve fiber in DRG, infiltration of inflammation cells, and reduction 
of the intraepidermal nerve fiber (IENFD) count [2]. As HIV itself cannot directly 
infect nerve bodies, destruction of neuron in HIV-SN may be caused by neurotoxic 
agents released by activated macrophage and satellite glial cells (TNF-α, IL-1β, 
chemokines), viral proteins with neurotoxic properties (gp41, gp120, Tat, Vpr), 
infection of perineural cells, or combinations of these processes [54–58]. A study in 
simian immunodeficiency virus macaque model confirmed that HIV infection acti-
vates perineuronal inflammatory cells (including macrophages and lymphocytes) 
in trigeminal ganglia and DRG during the early stage of infection. In the later stage, 
neuronal damage becomes evident, and regenerative capacity of small epidermal 
nerve is impaired [59].
HIV infection may cause macrophages to respond to the axonal degenera-
tion (even in mild cases) causing inflammation of the nerves and DRG. Pro-
inflammatory mediators were released by Schwann cells at DRG and may 
accumulate adjacent to peripheral nerves, activate apoptotic pathways and cause 
damage to the nerves directly or indirectly (reviewed in [55]). The gp120 virus 
protein may act directly on chemokine receptors expressed on neurons and cause 
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pain [60]. A histopathology study of skin biopsies from HIV-SN patients on ART 
without stavudine confirmed the presence of inflammatory macrophages and T 
cells expressing some chemokine receptors (CX3CR1, CCR2, CCR5), along with 
reduced IENFD [61].
HIV protein gp120 is a component of the viral glycoprotein sheath. The 
entry of the HIV virus into cells requires the interaction of gp120 with CD4 
glycoprotein and a chemokine receptor (usually CXCR4 and/or CCR5) which 
may be expressed on neurons or infiltrating inflammatory cells. Several che-
mokine receptors, such as CCR2, CCR5, and CXCR4, and CX3CR1 (fractalkine 
receptor) are located in primary afferent neurons or secondary neurons of the 
spinal dorsal horn. Chemokines and gp120 can cause pain through direct effects 
on chemokine receptors expressed by nociceptive neurons [62]. For example, 
binding of gp120 to CXCR4 receptors increases the release of CCL5, which binds 
CCR5 and triggers the release of TNFα and other neurotoxic substances. These 
interactions activate an influx of Ca2+, kinase cascades, and STAT3 signaling 
leading to the signs and symptoms of HIV-SN. The pathways have been reviewed 
previously [61, 63].
The pathophysiology of HIV-SN in patients on stavudine may reflect damage 
to the mitochondria of neurons and axons via damage to mitochondrial DNA 
(mtDNA) [64]. Inhibition of mtDNA gamma polymerase, mtDNA intercalation, 
and damage in stress response of mitochondria has been demonstrated in vitro 
in cultures of T-lymphoblastoid cells [65]. This finding is further supported 
by differences in haplotypes or SNP in mtDNA in Europeans, Hispanics, and 
Africans that may contribute to differences in the prevalence of HIV-SN [36, 52, 
66, 67].
6. Therapeutic options
Management of HIV-SN aims to avoid further nerve damage and minimize the 
patients’ symptoms especially neuropathic pain. Some studies showed that smoked 
cannabis is effective and has analgesic value to relieve pain in HIV-SN patients 
[68, 69]. However, due to legal issues in many countries, the recommendation of 
smoked cannabis has been controversial. Other pharmacological treatments recom-
mended for neuropathic pain are amitriptyline, pregabalin, and gabapentin [70]. 
However, these medications were not superior to the placebo in HIV-SN patients 
[71–73]. Another option is non-pharmacological treatment such as acupuncture 
and hypnosis. However, acupuncture was not superior to the placebo to improve 
pain in HIV patients [74]. A small study showed that hypnosis showed benefit to 
reduce the pain score in HIV-SN patients [75].
7. Conclusions and future directions
Despite the withdrawal of the most toxic drugs from recommended ART 
regimens, HIV-SN remains a common neurological complication of HIV disease. 
The risk factors of HIV-SN have changed with changes in ART from the patient’s 
age and height to the efficacy of ART and the use of protease inhibitors. Genetic 
polymorphisms that influence pathogenesis of HIV-SN will provide candidate 
molecules, which may contribute to pathogenesis, but studies of skin biopsies from 
patients are needed to confirm the roles of the encoded proteins. Animal models 
may reveal mechanisms for neuropathy and pain by HIV proteins but do not mimic 
the complexities of HIV disease in patients.
7© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
HIV-Associated Sensory Neuropathy
DOI: http://dx.doi.org/10.5772/intechopen.81176
Author details
Fitri Octaviana1,2*, Ahmad Yanuar Safri1,2, Darma Imran1,2 and Patricia Price1,3,4
1 Neurology Department, Faculty of Medicine, Universitas Indonesia,  
Jakarta, Indonesia
2 Neurology Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
3 School of Biomedical Sciences, Curtin University, Bentley, Australia
4 School of Physiology, University of Witwatersrand, Johannesburg, South Africa
*Address all correspondence to: fitri.octaviana@gmail.com
8Demystifying Polyneuropathy - Recent Advances and New Directions
[1] Pardo CA, McArthur JC, Griffin 
JW. HIV neuropathy: Insights in the 
pathology of HIV peripheral nerve 
disease. Journal of the Peripheral 
Nervous System. 2001;6:21-27
[2] Schütz SG, Robinson-Papp J.  
HIV-related neuropathy: Current 
perspectives. HIV AIDS. 2013;5:243-251
[3] Anziska Y, Helzner EP, Crystal H, 
Glesby MJ, Plankey M, Weber K, et al. 
The relationship between race and HIV-
distal sensory polyneuropathy in a large 
cohort of US women. Journal of the 
Neurological Sciences. 2012;315:129-132
[4] Morgello S. HIV-associated distal 
sensory polyneuropathy in the era of 
highly active antiretroviral therapy: The 
Manhattan HIV Brain Bank. Archives of 
Neurology. 2004;61:546-551
[5] Dubey TN, Raghuvanshi SS, Sharma 
H, Saxena R. HIV neuropathy in pre-
HAART patients and it’s correlation 
with risk factors in Central India. 
Neurology India. 2013;61:478-480
[6] Centner CM, Little F, Van, Der Watt 
JJ, Vermaak J-R, Dave JA, Levitt NS, 
et al. Evolution of sensory neuropathy 
after initiation of antiretroviral therapy: 
HIV-DSP evolution on ART. Muscle & 
Nerve. 2018;57:371-379
[7] Cherry CL, Affandi JS, Imran D, 
Yunihastuti E, Smyth K, Vanar S, et al. 
Age and height predict neuropathy 
risk in patients with HIV prescribed 
stavudine. Neurology. 2009;73:315-320
[8] Octaviana F, Safri AY, Setiawan DD, 
Estiasari R, Imran D, Ranakusuma T, 
et al. Detectable plasma HIV RNA is 
associated with sensory neuropathy 
in HIV patients treated without 
stavudine. Journal of Acquired 
Immune Deficiency Syndromes. 2018. 
publish ahead of print. DOI: 10.1097/
QAI.0000000000001836
[9] Gonzalez-Duarte A, Robinson-
Papp J, Simpson DM. Diagnosis 
and management of HIV-associated 
neuropathy. Neurologic Clinics. 
2008;26:821-832
[10] Centner CM, Bateman KJ, 
Heckmann JM. Manifestations of 
HIV infection in the peripheral 
nervous system. Lancet Neurology. 
2013;12:295-309
[11] Robinson-Papp J, Gonzalez-Duarte 
A, Simpson DM, Rivera-Mindt M, 
Morgello S. The roles of ethnicity 
and antiretrovirals in HIV-associated 
polyneuropathy: A pilot study. Journal 
of Acquired Immune Deficiency 
Syndromes. 2009;51:569-573
[12] Wadley AL, Hendry LM, Kamerman 
PR, Chew CS, Price P, Cherry CL, 
et al. Role of TNF block genetic 
variants in HIV-associated sensory 
neuropathy in black southern Africans. 
European Journal of Human Genetics. 
2015;23:363-368
[13] Wadley AL, Kamerman PR, Chew 
CSN, Lombard Z, Cherry CL, Price P. A 
polymorphism in IL4 may associate 
with sensory neuropathy in African 
HIV patients. Molecular Immunology. 
2013;55:197-199
[14] Goullee H, Wadley AL, Cherry CL, 
Allcock RJN, Black M, Kamerman PR, 
et al. Polymorphisms in CAMKK2 may 
predict sensory neuropathy in African 
HIV patients. Journal of Neurovirology. 
2016;22:508-517
[15] Affandi JS, Price P, Imran D, 
Yunihastuti E, Djauzi S, Cherry CL. Can 
we predict neuropathy risk before 
stavudine prescription in a resource-
limited setting? AIDS Research and 
Human Retroviruses. 2008;24:1281-1284
[16] Chew CSN, Cherry CL, Imran 
D, Yunihastuti E, Kamarulzaman 
A, Varna S, et al. Tumour necrosis 
References
9HIV-Associated Sensory Neuropathy
DOI: http://dx.doi.org/10.5772/intechopen.81176
factor haplotypes associated with 
sensory neuropathy in Asian and 
Caucasian human immunodeficiency 
virus patients. Tissue Antigens. 
2011;77:126-130
[17] Hahn K, Husstedt I. HIV associated 
neuropathies. In: HIV Infection in the 
Era of Highly Active Antiretroviral 
Treatment and Some of Its Association 
[Internet]. IntechOpen; 2011 [cited 
2018 Jun 5]. p. 15. Available from: 
https://www.intechopen.com/books/
hiv-infection-in-the-era-of-highly-
active-antiretroviral-treatment-and-
some-of-its-associated-complications
[18] Phillips TJC, Brown M, Ramirez JD, 
Perkins J, Woldeamanuel YW, Williams 
AC de C, et al. Sensory, psychological, 
and metabolic dysfunction in HIV-
associated peripheral neuropathy: A 
cross-sectional deep profiling study. 
Pain. 2014;155:1846-1860
[19] Ellis RJ, Evans SR, Clifford 
DB, Moo LR, McArthur JC, Collier 
AC, et al. Clinical validation of the 
NeuroScreen. Journal of Neurovirology. 
2005;11:503-511
[20] Misra UK, Kalita J, Nair PP. 
Diagnostic approach to peripheral 
neuropathy. Annals of Indian Academy 
of Neurology. 2008;11:89-97
[21] Brew BJ. The peripheral 
nerve complications of human 
immunodeficiency virus (HIV) infection. 
Muscle & Nerve. 2003;28:542-552
[22] Kokotis P, Schmelz M, Skopelitis 
EE, Kordossis T, Karandreas N. 
Differential sensitivity of thick and 
thin fibers to HIV and therapy-induced 
neuropathy. Autonomic Neuroscience. 
2007;136:90-95
[23] Kokotis P, Schmelz M, Papadimas 
GK, Skopelitis EE, Aroni K, Kordossis 
T, et al. Polyneuropathy induced 
by HIV disease and antiretroviral 
therapy. Clinical Neurophysiology. 
2013;124:176-182
[24] Teoh HL, Chow A, Wilder-Smith 
E. Skin wrinkling for diagnosing 
small fibre neuropathy: Comparison 
with epidermal nerve density and 
sympathetic skin response. Journal 
of Neurology, Neurosurgery, and 
Psychiatry. 2008;79:835-837
[25] Ping Ng KW, Ong JJY, Nyein Nyein 
TD, Liang S, Chan YC, Lee KO, et al. 
EMLA-induced skin wrinkling for 
the detection of diabetic neuropathy. 
Frontiers in Neurology. 2013;4:1-7
[26] Wilder-Smith E, Chow A. Water 
immersion and EMLA cause 
similar digit skin wrinkling and 
vasoconstriction. Microvascular 
Research. 2003;66:68-72
[27] Boger MS, Hulgan T, Haas DW, 
Mitchell V, Smith AG, Singleton JR, et al. 
Measures of small-fiber neuropathy 
in HIV infection. Autonomic 
Neuroscience. 2012;169:56-61
[28] Lauria G, Cornblath DR, Johansson 
O, McArthur JC, Mellgren SI, Nolano M, 
et al. EFNS guidelines on the use of skin 
biopsy in the diagnosis of peripheral 
neuropathy. European Journal of 
Neurology. 2005;12:747-758
[29] Van Acker N, Ragé M, Sluydts 
E, Knaapen MWM, De Bie M, 
Timmers M, et al. Automated PGP9.5 
immunofluorescence staining: A 
valuable tool in the assessment of small 
fiber neuropathy? BMC Research Notes. 
2016;9:280-290
[30] Zhou L, Kitch DW, Evans SR, 
Hauer P, Raman S, Ebenezer GJ, et al. 
Correlates of epidermal nerve fiber 
densities in HIV-associated distal 
sensory polyneuropathy. Neurology. 
2007;68:2113-2119
[31] Childs EA, Lyles RH, Selnes OA, 
Chen B, Miller EN, Cohen BA, et al. 
Plasma viral load and CD4 lymphocytes 
predict HIV-associated dementia 
and sensory neuropathy. Neurology. 
1999;52:607-613
Demystifying Polyneuropathy - Recent Advances and New Directions
10
[32] Tagliati M, Grinnell J, Godbold J, 
Simpson DM. Peripheral nerve function 
in HIV infection. Archives of Neurology. 
1999;56:84-89
[33] Evans SR, Ellis RJ, Chen H, Yeh T, 
Lee AJ, Schifitto G, et al. Peripheral 
neuropathy in HIV: Prevalence and risk 
factors. AIDS. 2011;25:919-928
[34] Nakamoto BK, McMurtray A, Davis 
J, Valcour V, Watters MR, Shiramizu 
B, et al. Incident neuropathy in HIV-
infected patients on HAART. AIDS 
Research and Human Retroviruses. 
2010;26:759-765
[35] Pettersen JA, Jones G, Worthington 
C, Krentz HB, Keppler OT, Hoke A, 
et al. Sensory neuropathy in human 
immunodeficiency virus/acquired 
immunodeficiency syndrome 
patients: Protease inhibitor–mediated 
neurotoxicity. Annals of Neurology. 
2006;59:816-824
[36] Holzinger ER, Hulgan T, Ellis RJ, 
Samuels DC, Ritchie MD, Haas DW, 
et al. Mitochondrial DNA variation and 
HIV-associated sensory neuropathy in 
CHARTER. Journal of Neurovirology. 
2012;18:511-520
[37] Cherry CL, Rosenow A, Affandi 
JS, McArthur JC, Wesselingh SL, 
Price P. Cytokine genotype suggests 
a role for inflammation in nucleoside 
analog-associated sensory neuropathy 
(NRTI-SN) and predicts an individual’s 
NRTI-SN risk. AIDS Research and 
Human Retroviruses. 2008;24:117-123
[38] Makoto T, Hidetoshi T-S, Kazuhide 
I. P2X4R and P2X7R in neuropathic 
pain. WIREs Membrane Transport and 
Signaling. 2012;1:513-521
[39] Kawasaki Y, Zhang L, Cheng J-K, Ji 
R-R. Cytokine mechanisms of central 
sensitization: Distinct and overlapping 
role of interleukin-1beta, interleukin-6, 
and tumor necrosis factor-alpha in 
regulating synaptic and neuronal 
activity in the superficial spinal 
cord. The Journal of Neuroscience. 
2008;28:5189-5194
[40] Kataoka A, Tozaki-Saitoh H, Koga 
Y, Tsuda M, Inoue K. Activation of P2X7 
receptors induces CCL3 production in 
microglial cells through transcription 
factor NFAT. Journal of Neurochemistry. 
2009;108:115-125
[41] Shiratori M, Tozaki-Saitoh H, 
Yoshitake M, Tsuda M, Inoue K. P2X7 
receptor activation induces CXCL2 
production in microglia through NFAT 
and PKC/MAPK pathways. Journal of 
Neurochemistry. 2010;114:810-819
[42] Guo L-H, Trautmann K, 
Schluesener HJ. Expression of P2X4 
receptor by lesional activated microglia 
during formalin-induced inflammatory 
pain. Journal of Neuroimmunology. 
2005;163:120-127
[43] Tsuda M, Kuboyama K, Inoue T,  
Nagata K, Tozaki-Saitoh H, Inoue K.  
Behavioral phenotypes of mice lacking 
purinergic P2X4 receptors in acute and 
chronic pain assays. Molecular Pain. 
2009;5:28-34
[44] Tsuda M, Masuda T, Tozaki-
Saitoh H, Inoue K. P2X4 receptors and 
neuropathic pain. Frontiers in Cellular 
Neuroscience. 2013;7:191
[45] Toulme E, Khakh BS. Imaging 
P2X4 receptor lateral mobility in 
microglia: Regulation by calcium and 
p38 MAPK. The Journal of Biological 
Chemistry. 2012;287:14734-14748
[46] Trang T, Beggs S, Wan X, Salter 
MW. P2X4-receptor-mediated 
synthesis and release of brain-derived 
neurotrophic factor in microglia 
is dependent on calcium and p38-
mitogen-activated protein kinase 
activation. The Journal of Neuroscience. 
2009;29:3518-3528
[47] Zhang X, Guo L, Collage RD, 
Stripay JL, Tsung A, Lee JS, et al. 
11
HIV-Associated Sensory Neuropathy
DOI: http://dx.doi.org/10.5772/intechopen.81176
Calcium/calmodulin-dependent protein 
kinase (CaMK) Ialpha mediates the 
macrophage inflammatory response to 
sepsis. Journal of Leukocyte Biology. 
2011;90:249-261
[48] Wayman GA, Lee Y-S, Tokumitsu 
H, Silva AJ, Soderling TR. Calmodulin-
kinases: Modulators of neuronal 
development and plasticity. Neuron. 
2008;59:914-931
[49] Gaff J, Halstrom S, Temple 
SEL, Baltic S, Kamerman P, Price 
P. Polymorphisms in P2X4R and 
CAMKK2 may affect TNFα production: 
Implications for a role in HIV-
associated sensory neuropathy. Human 
Immunology. 2018;79:224-227
[50] Hulgan T, Levinson RT, 
Gerschenson M, Phanuphak N, 
Ananworanich J, Teeratakulpisarm N, 
et al. Epidermal nerve fiber density, 
oxidative stress, and mitochondrial 
haplogroups in HIV-infected 
Thais initiating therapy. AIDS. 
2014;28:1625-1633
[51] Drakesmith H, Chen N, Ledermann 
H, Screaton G, Townsend A, Xu 
X-N. HIV-1 Nef down-regulates 
the hemochromatosis protein HFE, 
manipulating cellular iron homeostasis. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2005;102:11017-11022
[52] Kallianpur AR, Hulgan T, Canter 
JA, Ritchie MD, Haines JL, Robbins GK, 
et al. Hemochromatosis (HFE) gene 
mutations and peripheral neuropathy 
during antiretroviral therapy. AIDS. 
2006;20:1503-1513
[53] Kallianpur AR, Jia P, Ellis RJ, Zhao 
Z, Bloss C, Wen W, et al. Genetic 
variation in iron metabolism is 
associated with neuropathic pain and 
pain severity in HIV-infected patients 
on antiretroviral therapy. PLoS One. 
2014;9:e103123
[54] Abbadie C, Bhangoo S, De YK, 
Malcangio M, Melik-Parsadaniantz 
S, White FA. Chemokines and pain 
mechanisms. Brain Research Reviews. 
2009;60:125-134
[55] Kamerman PR, Moss PJ, Weber 
J, Wallace VCJ, Rice ASC, Huang 
W. Pathogenesis of HIV-associated 
sensory neuropathy: Evidence from 
in vivo and in vitro experimental 
models. Journal of the Peripheral 
Nervous System. 2012;17:19-31
[56] Acharjee S, Noorbakhsh F, 
Stemkowski PL, Olechowski C, Cohen 
EA, Ballanyi K, et al. HIV-1 viral 
protein R causes peripheral nervous 
system injury associated with in vivo 
neuropathic pain. The FASEB Journal. 
2010;24:4343-4353
[57] Melli G, Keswani SC, Fischer A, 
Chen W, Höke A. Spatially distinct and 
functionally independent mechanisms 
of axonal degeneration in a model of 
HIV-associated sensory neuropathy. 
Brain. 2006;129:1330-1338
[58] Hahn K, Robinson B, Anderson 
C, Li W, Pardo CA, Morgello S, et al. 
Differential effects of HIV infected 
macrophages on dorsal root ganglia 
neurons and axons. Experimental 
Neurology. 2008;210:30-40
[59] Mangus LM, Dorsey JL, Laast VA, 
Ringkamp M, Ebenezer GJ, Hauer P, 
et al. Unraveling the pathogenesis of 
HIV peripheral neuropathy: Insights 
from a simian immunodeficiency 
virus macaque model. ILAR Journal. 
2014;54:296-303
[60] Hao S. The molecular and 
pharmacological mechanisms of 
HIV-related neuropathic pain. Current 
Neuropharmacology. 2013;11:499-512
[61] Mountford J, Octaviana F, Estiasari 
R, Setiawan DD, Ariyanto I, Lee S, 
et al. Ex vivo expression of chemokine 
receptors on cells surrounding 
Demystifying Polyneuropathy - Recent Advances and New Directions
12
cutaneous nerves in patients with HIV-
associated sensory neuropathy. AIDS. 
2018;32:431-441
[62] Oh SB, Tran PB, Gillard SE, 
Hurley RW, Hammond DL, Miller 
RJ. Chemokines and glycoprotein120 
produce pain hypersensitivity by 
directly exciting primary nociceptive 
neurons. The Journal of Neuroscience. 
2001;21:5027-5035
[63] Kiguchi N, Kobayashi Y, Kishioka 
S. Chemokines and cytokines in 
neuroinflammation leading to 
neuropathic pain. Current Opinion in 
Pharmacology. 2012;12:55-61
[64] Lehmann HC, Chen W, Borzan J, 
Mankowski JL, Höke A. Mitochondrial 
dysfunction in distal axons contributes 
to human immunodeficiency virus 
sensory neuropathy. Annals of 
Neurology. 2011;69:100-110
[65] Höschele D. Cell culture models 
for the investigation of NRTI-induced 
mitochondrial toxicity. Toxicology In 
Vitro. 2006;20:535-546
[66] Canter JA, Haas DW, Kallianpur 
AR, Ritchie MD, Robbins GK, 
Shafer RW, et al. The mitochondrial 
pharmacogenomics of haplogroup T: 
MTND2*LHON4917G and antiretroviral 
therapy-associated peripheral 
neuropathy. The Pharmacogenomics 
Journal. 2008;8:71-77
[67] Canter JA, Robbins GK, Selph D, 
Clifford DB, Kallianpur AR, Shafer 
R, et al. African mitochondrial DNA 
subhaplogroups and peripheral 
neuropathy during antiretroviral 
therapy. The Journal of Infectious 
Diseases. 2010;201:1703-1707
[68] Abrams DI, Jay CA, Shade SB, 
Vizoso H, Reda H, Press S, et al. 
Cannabis in painful HIV-associated 
sensory neuropathy: A randomized 
placebo-controlled trial. Neurology. 
2007;68:515-521
[69] Ellis RJ, Toperoff W, Vaida F, 
Van Den Brande G, Gonzales J, 
Gouaux B, et al. Smoked medicinal 
cannabis for neuropathic pain in HIV: 
A randomized, crossover clinical 
trial. Neuropsychopharmacology. 
2009;34:672-680
[70] Finnerup NB, Attal N, 
Haroutounian S, McNicol E, Baron R, 
Dworkin RH, et al. Pharmacotherapy 
for neuropathic pain in adults: A 
systematic review and meta-analysis. 
Lancet Neurology. 2015;14:162-173
[71] Kieburtz K, Simpson D, Yiannoutsos 
C, Max M, Hall C, Ellis RJ, et al. A 
randomized trial of amitriptyline and 
mexiletine for painful neuropathy 
in HIV infection. AIDS clinical trial 
group 242 protocol team. Neurology. 
1998;51:1682-1688
[72] Simpson DM, Schifitto G, 
Clifford DB, Murphy TK, Cruz ED-D, 
Glue P, et al. Pregabalin for painful HIV 
neuropathy. Neurology. 2010;74:413-420
[73] Hahn K, Arendt G, Braun JS, Giesen 
H-J, Husstedt IW, Maschke M, et al. A 
placebo-controlled trial of gabapentin 
for painful HIV-associated sensory 
neuropathies. Journal of Neurology. 
2004;251:1260-1266
[74] Shlay JC. Acupuncture and 
amitriptyline for pain due to HIV-
related peripheral neuropathy: A 
randomized controlled trial. Journal 
of the American Medical Association. 
1998;280:1590-1595
[75] Dorfman D, George MC, Schnur J, 
Simpson DM, Davidson G, Montgomery 
G. Hypnosis for treatment of HIV 
neuropathic pain: A preliminary report. 
Pain Medicine. 2013;14:1048-1056
